Clyde will be updating delegates on the recent changes to ICH-S7B/E14 and how hiPSc cardiomyocytes can help fulfil regulatory compliance and also reduce late stage cardiovascular safety failures.
Read MoreGossamer Bio, Inc., one of Clyde’s clients, has recently published a series of case studies to highlight the benefits of hiPSC cardiomyocytes for early identification of a broad set of cardiovascular liabilities. These case studies show that hiPSC-CM assay can assess drug-induced negative inotropy as well as electrical conduction alterations.
Read MoreClyde Biosciences is the leading in vitro cardiomyocyte safety provider with a track record in developing fully validated safety assays to help solve industry wide challenges regarding cardiovascular liabilities beyond that of hERG. Working with the FDA and large pharmas, Clyde has been instrumental in developing next generation assays for pro arrhythmic risk (CiPA Assay) and negative inotropy (CRACKIT). This publication in the Journal of Cardiovascular Pharmacology highlights our excitation-coupling assay for the parallel assessment of voltage and contractility effects using hiPSC cardiomyocytes.
Read MoreIt has been long established that a hERG assay is not a sufficient predictor for pro-arrythmic actions of a drug (Gintant, 2011; Lu et al., 2008). Since 2013, the FDA has led an initiative designed to validate the use of hiPSC cardiomyocytes in an assay to improve prediction of drug-induced pro-arrhythmic risk (Comprehensive invitro Pro-arrythmia Assay – CiPA). This initiative has stimulated the use if iPSC-cardiomyocytes in industrial work and a growing number of regulatory filings now contain data from iPSC cardiomyocytes.
Read MoreClyde Biosciences (Clyde) today announced that the major NC3Rs Crackit Inpulse study demonstrated the accuracy of its CellOPTIQ® technology in predicting the cardiac side-effect risk of drugs. Clyde’s platform provided the majority of data in this large study, a collaboration amongst Clyde’s laboratory, GSK, and Professor Chris Denning at Nottingham University..’ […]
Read MoreClyde Biosciences is delighted to announce it has demonstrated superiority over the legacy MEA system in the recent international CiPA study. Initiated by the FDA and by the Health and Environment Sciences Institute, the CiPA study pitted Clyde Biosciences’ CellOPTIQ system against the established micro-electrode array. The results of the study confirmed that Clyde Biosciences’ […]
Read MoreThe Clyde Biosciences team are delighted to have been shortlisted for an award in February’s Scottish Life Sciences Awards. One of three finalists in the Innovative Collaboration award, Clyde has been recognised for its contribution to a global initiative designed to improve the way drugs are assessed for cardiac safety. The initiative, known as CiPA […]
Read MoreClyde Biosciences has been recognised in The Scotsman newspaper (December 1, 2017) as a leading innovator in Scottish life sciences. Alongside other Scottish companies, Clyde was noted for its recent project with AstraZeneca examining the effects of certain drug compounds on cardiac cells. Clyde’s unique optical cell function assay service provides information to biotech and […]
Read MoreHighlights Clyde Biosciences were delighted to present a total of four posters at the recent SPS meeting in Berlin, representing collobarations with major pharmaceutical companies. The posters showed: The influence of fibroblast co-culture and 3D structures on cardiac action potentials of human stem cell derived cardiomyocytes (Collaboration with Abbvie) AbbVie SPS FINAL Measurements of voltage, intracellular […]
Read MoreClyde Biosciences Presents Four Posters at SPS 2017 Highlights Clyde Biosciences were delighted to present a total of four posters at the recent SPS meeting in Berlin, representing collobarations with major pharmaceutical companies. The posters showed: The influence of fibroblast co-culture and 3D structures on cardiac action potentials of human stem cell derived cardiomyocytes (Collaboration […]
Read MoreRecent Publication Highlights Flexibility and Power of Clyde’s CellOPTIQ® Assay Highlights Collaboration with AZ on kinase inhibitor induced cardiotoxicity Understanding E-C coupling is essential in kinase research CellOPTIQ® is the only single mechanistic screen providing insight into E-C coupling mechanism Observing the interplay between voltage, calcium transient and contractility is vital and is only available […]
Read MoreWelcome to our new site – Clyde Biosciences is delighted to launch our new website. Have a good look around and please get in touch with feedback or inquiries.
Read MoreClyde Biosciences Autumn Business Update Highlights CiPA 28 study finished and data submitted weeks ahead of schedule New CellOPTIQ®-X contractility assay launched New Heart Failure model launched Clyde Biosciences today announces progress in its autumn business update. The company reports that in the last three months it has completed work on a number of important […]
Read MoreNEWHOUSE – Clyde Biosciences today announced the launch of a new service to serve the needs of its global pharma clients. CellOPTIQ®-X represents a revolution in contractility assays, offering: Early detection of contractility toxicities Higher throughput, cost-effective solution Reduction in animal requirements Accurate prediction of the human response Reduction in later stage attrition Heart cell […]
Read MoreClyde Biosciences is delighted to announce the appointment of Alan Johnston to the post of Chair. Alan brings a wealth of CRO experience to Clyde. He spent some 30 years with Inveresk Research (subsequently Charles River Laboratories) in Edinburgh, Alan had several Senior Management posts within Inversek and had responsibility for Commercial staff. He is now Trustee […]
Read MoreClyde Biosciences Ltd. (Clyde Biosciences) has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund. Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the round along with Glasgow University Holdings, Ltd. Clyde Biosciences, a spin-out company from the University of Glasgow, […]
Read More